GC
ALBO

Grimes & Company’s Albireo Pharma Inc ALBO Stock Holding History

Grimes & Company’s Portfolio ALBO Stock Details ALBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-8,191
Closed -$244K – 309
2022
Q1 		$244K Buy
+8,191
New +$240K 0.01% 261
2021
Q4 		– Sell
-8,242
Closed -$257K – 316
2021
Q3 		$257K Buy
8,242
+821
+11% +$25.4K 0.01% 258
2021
Q2 		$261K Buy
+7,421
New +$241K 0.01% 255

Other funds holding ALBO

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return

Grimes & Company's ALBO Position: Q2 2022 in Review

Grimes & Company sold out of Albireo Pharma Inc (ALBO) in Q2 2022, closing a stake of 8,191 shares — an estimated $244K sold.

Grimes & Company first reported a position in ALBO in Q2 2021 and held it in 3 quarters. The position peaked at $261K in Q2 2021. 103 funds tracked by Wall St. Rank hold ALBO as of Q2 2022.

  • Grimes & Company reported no remaining Albireo Pharma Inc position as of Q2 2022 after selling out during the quarter.
  • Grimes & Company sold 8,191 Albireo Pharma Inc shares in Q2 2022, an estimated $244K.
  • Grimes & Company first reported a position in Albireo Pharma Inc in Q2 2021 and held it in 3 quarters.
  • Grimes & Company's Albireo Pharma Inc position peaked at $261K in Q2 2021.
  • 103 funds tracked by Wall St. Rank held Albireo Pharma Inc as of Q2 2022.

Based on Grimes & Company's 13F filing for Q2 2022, filed 22 Jul 2022.